Navigation Links
Tomophase and MOSS, S.p.A. Expand OCTIS Technology Throughout Italy with New Distribution Agreement
Date:3/26/2013

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Tomophase Corporation, a leading developer of minimally invasive optical coherence tomography (OCT) tissue imaging devices, announced today that it has signed a distribution agreement with MOSS S.p.A. of Italy.

The distribution agreement with MOSS covers the Tomophase product line including the OCT Imaging System, OCTIS™ and the OCTIS Probes in the territory Italy and San Marino. Upon signing, MOSS also purchased two systems for waiting Italian clinicians who are experts in pulmonary imaging. Delivery and installation of OCTIS is scheduled for June. These new systems for Italian medical centers follow the deployment and installation of OCTIS in Germany at the Thoraxklinik, University of Heidelberg.  Both MOSS and Tomophase will work together to expand the availability of this innovative and much anticipated technology to the Italian medical community. 

"We are delighted to have MOSS as our distributor in Italy. President Franco Papa and his team have been very active with innovative imaging technologies and have been following our progress at Tomophase. We look forward to close cooperation with MOSS as they extend our OCTIS technology for interventional pulmonology throughout Italy," said Ralph Johnston , President and CEO. 

Dr. Peter Norris , Tomophase Executive Chairman commented, "The partnership of Tomophase with Franco Papa and MOSS is another example of the high level of international interest in the OCTIS platform. With their experience in Interventional Pulmonology, MOSS is an excellent fit for OCTIS and our goal of introducing physicians to the greatly expanded pulmonary imaging capabilities it affords. The placement of OCTIS units in two major pulmonary centers in Italy is a major step forward in meeting this goal."

Mr. Franco Papa , MOSS President and CEO, personally expressed, "MOSS has specialized through the years in identifying high-tech, innovative solutions which may provide concrete answers to our end users' most specific therapeutic demands. Therefore we welcome the opportunity to partner with an outstanding company like Tomophase for the purpose of developing the national market by means of such a strategic collaboration and, thus, achieve a successful introduction of the Tomophase OCT Imaging System in the field."

About MOSS
MOSS was founded to further the idea of creating an active platform for young and dynamic companies in order to offer foreign-based advanced medical device manufacturers a local, operating interface to support their needs and requirements throughout Italy. 

About Tomophase
Tomophase is a leader in developing bronchoscopic-based systems for interventional pulmonology. Offering significantly higher resolution than either CT scan or ultrasound, OCTIS provides real-time, high resolution, sub-surface tissue imaging of airways and lungs, to be followed by diagnostic and therapeutic applications. Our goal is to provide physicians with heretofore unobtainable airway microstructural images to improve the management and clinical outcome of pulmonary disease. The company has 28 patent and applications issued and pending. FDA 510(k) clearance for OCTIS was received and the CE Mark is expected in June. The U.S. commercial launch is underway and the EU rollout is proceeding. The company is currently raising investment capital to meet the increasing international demand for the OCT Imaging System.  Examples of our tissue imaging results are available at www.tomophase.com. For further information:In USA:Dr. Peter Norris, Executive Chairman 

Ralph Johnston, President, CEOTomophase CorporationTomophase CorporationP: (781) 229-57P: (781) 229-5700, ext 123 EmailEmailIn Italy: MOSS S.p.A.Via all'Erno, 528040 Lesa (NO) – ItalyTel. No.: +39 0322 772032Fax No.: +39 0322 292733EmailThis press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
2. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
3. Galderma, One of the Leading Pharmaceutical Companies, Relies on Verizon Enterprise Solutions to Provide Expanded, Secure Global Communications Platform
4. Torrance Memorial Medical Center Boosts Patient Safety With Expanded Use Of Capnography Technology
5. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
6. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
7. PET/MR Scanner Holds Promise For Expanded Diagnostics
8. BioElectronics Expands European Distribution to Malta
9. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Hyland Software and Merge Healthcare Expand Partnership to Provide Best of Breed ECM and VNA Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):